Active substances
Captopril + Hydrochlorothiazide
- SFDA 1
- US FDA 9
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CAPOZIDE TABLET | 50, 25 mg | Tablet · Oral use | 28 Blister | SAR 73.00 | NCE · Prescription | BRISTOL-MYERS SQUIBB | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CAPTOPRIL AND HYDROCHLOROTHIAZIDE | 25MG;15MG; 25MG;25MG; 50MG;25MG; 50MG;15MG | tablet · oral | RISING | Prescription | 29 Dec 1997 |
| CAPOZIDE 25/15 | 25MG;15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | APOTHECON | Discontinued | 12 Oct 1984 |
| CAPOZIDE 25/25 | 25MG;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | APOTHECON | Discontinued | 12 Oct 1984 |
| CAPOZIDE 50/25 | 50MG;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | APOTHECON | Discontinued | 12 Oct 1984 |
| CAPOZIDE 50/15 | 50MG;15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | APOTHECON | Discontinued | 12 Oct 1984 |
| CAPTOPRIL AND HYDROCHLOROTHIAZIDE | 25MG;15MG; 25MG;25MG; 50MG;25MG; 50MG;15MG | tablet · oral | STRIDES PHARMA INTL | Discontinued | 29 Dec 1997 |
| CAPTOPRIL AND HYDROCHLOROTHIAZIDE | 25MG;15MG; 25MG;25MG; 50MG;25MG; 50MG;15MG | tablet · oral | COSETTE PHARMS NC | Discontinued | 29 Dec 1997 |
| CAPTOPRIL AND HYDROCHLOROTHIAZIDE | 50MG;25MG | tablet · oral | WATSON LABS | Discontinued | 29 Dec 1997 |
| CAPTOPRIL AND HYDROCHLOROTHIAZIDE | 25MG;15MG; 25MG;25MG; 50MG;25MG; 50MG;15MG | tablet · oral | IVAX SUB TEVA PHARMS | Discontinued | 18 Jun 1998 |
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.